Literature DB >> 15486023

Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign.

Almer M van der Sloot1, Margaret M Mullally, Gregorio Fernandez-Ballester, Luis Serrano, Wim J Quax.   

Abstract

Protein thermal stability is important for therapeutic proteins, both influencing the pharmacokinetic and pharmacodynamic properties and for stability during production and shelf-life of the final product. In this paper we show the redesign of a therapeutically interesting trimeric all-beta-sheet protein, the cytokine TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), yielding variants with improved thermal stability. A combination of tumor necrosis factor (TNF) ligand family alignment information and the computational design algorithm PERLA was used to propose several mutants with improved thermal stability. The design was focused on non-conserved residues only, thus reducing the use of computational resources. Several of the proposed mutants showed a significant increase in thermal stability as experimentally monitored by far-UV circular dichroism thermal denaturation. Stabilization of the biologically active trimer was achieved by monomer subunit or monomer-monomer interface modifications. A double mutant showed an increase in apparent T(m) of 8 degrees C in comparison with wild-type TRAIL and remained biologically active after incubation at 73 degrees C for 1 h. To our knowledge, this is the first study that improves the stability of a large multimeric beta-sheet protein structure by computational redesign. A similar approach can be used to alter the characteristics of other multimeric proteins, including other TNF ligand family members.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486023     DOI: 10.1093/protein/gzh079

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  8 in total

1.  A simplified method for the efficient purification and refolding of recombinant human TRAIL.

Authors:  Zhenjiang Zhang; Su Bin Hahn; Thong M Cao; Michael R King
Journal:  Biotechnol Prog       Date:  2020-05-11

2.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Authors:  Almer M van der Sloot; Vicente Tur; Eva Szegezdi; Margaret M Mullally; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

3.  Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.

Authors:  Eva Szegezdi; Almer M van der Sloot; Devalingam Mahalingam; Lynda O'Leary; Robbert H Cool; Inés G Muñoz; Guillermo Montoya; Wim J Quax; Steven de Jong; Afshin Samali; Luis Serrano
Journal:  Mol Cell Proteomics       Date:  2012-01-02       Impact factor: 5.911

4.  Targeting AML through DR4 with a novel variant of rhTRAIL.

Authors:  Eva Szegezdi; Carlos R Reis; Almer M van der Sloot; Alessandro Natoni; Aoife O'Reilly; Janice Reeve; Robbert H Cool; Michael O'Dwyer; Steven Knapper; Luis Serrano; Wim J Quax; Afshin Samali
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

5.  The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.

Authors:  Seema-Maria Nathwani; Lisa M Greene; Stefania Butini; Giuseppe Campiani; D Clive Williams; Afshin Samali; Eva Szegezdi; Daniela M Zisterer
Journal:  Int J Oncol       Date:  2016-05-12       Impact factor: 5.650

6.  RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL).

Authors:  Marc Tarrus; Almer M van der Sloot; Kai Temming; Marie Lacombe; Frank Opdam; Wim J Quax; Grietje Molema; Klaas Poelstra; Robbert J Kok
Journal:  Apoptosis       Date:  2008-02       Impact factor: 4.677

7.  GroEL/ES mediated the in vivo recovery of TRAIL inclusion bodies in Escherichia coli.

Authors:  Zhanqing Wang; Min Zhang; Xin Lv; Jiying Fan; Jian Zhang; Jing Sun; Yaling Shen
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

8.  CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation.

Authors:  Bin Liu; Olivia Adaly Diaz Arguello; Deng Chen; Siwei Chen; Ali Saber; Hidde J Haisma
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.